Patients with advanced BRCA-mutated breast cancer found no overall survival benefit with talazoparib
ABSTRACT: CTO71
New data from the Phase III EMBRACA trial led by researchers at The University of Texas MD Anderson Cancer Center found the PARP inhibitor talazoparib did not demonstrate a statistically significant overall survival (OS) benefit for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes. Most patients included in the study went on to receive subsequent systemic therapies, which...
MD Anderson, Ipsen advance new therapy with potential benefit for underserved lung and ovarian cancer patients
ABSTRACT: DDT01-03
In a first-time disclosure of IPN60090, a small-molecule inhibitor of the metabolic enzyme glutaminase (GLS1), researchers...
MD Anderson genetics expert Guillermina Lozano elected to American Academy of Arts and Sciences
Guillermina Lozano, Ph.D., chair of Genetics at The University of Texas MD Anderson Cancer Center, has been elected as...
Majority of patients responded in CAR T-cell trial for mantle cell lymphoma
A one-year follow-up study led by The University of Texas MD Anderson Cancer Center revealed a majority of patients with mantle cell lymphoma resistant to prior therapies may benefit from treatment with CD19-targeting chimeric antigen receptor (CAR) T-cell therapy. Findings were published in the April 1online issue of the New England Journal of Medicine.
The multi-center, 20-site, Phase II ZUMA-2 study reported that 93% of patients...
Immunotherapy effective in metastatic prostate cancers with specific markers of immune activation
Although metastatic castration-resistant prostate cancer (mCRPC) typically has limited response to immunotherapy, a subset of patients with...